Technology | Cath Lab | February 07, 2018

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares

Latest versions of 0.035-inch snares offer clinical versatility in retrieving or repositioning intravascular devices for peripheral procedures

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares

February 7, 2018 — Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch of new versions of its Expro Elite and Sympro Elite Snares for manipulating interventional devices in peripheral procedures.

Both the Expro Elite and Sympro Elite Snares represent next-generation versions of the 0.035-inch interventional snares originally launched in the U.S. in 2008 by Vascular Solutions, now a wholly-owned subsidiary of Teleflex Inc.

Stewart Strong, president and general manager of the Interventional business unit of Teleflex, said both snare products feature:

  • A durable nitinol construction that retains its shape and adds strength;
  • A radiopaque gold-plated tungsten coil and tip for enhanced visibility;
  • 1:1 torque response for controlled positioning and better access to distal targets; and
  • A unique locking handle that facilitates secure capture.

The Expro Elite Snare uses a helical loop for capture in all directions. The Sympro Elite Snare uses a 90-degree loop that remains coaxial to the vessel lumen for easy capture. Both snare products feature a preassembled, one-piece design that allows rapid deployment through any 0.035-inch compatible lumen. Both the Expro Elite and Sympro Elite Snares are available in 5, 10, 15, 25 and 35 mm loop diameters for clinical versatility. Both snares are 150 cm in length and are packaged one per box.

Both snares are intended for use in the cardiovascular system and hollow viscus to retrieve and/or manipulate objects using minimally-invasive surgical procedures. Manipulation procedures include retrieval and/or repositioning of intravascular foreign objects such as coils, balloons, catheters, and/or guidewires within the cardiovascular system. The devices are not intended for use in the coronary arteries or neurovasculature.

For more information: www.teleflex.com

 

Related Content

Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is a walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Overlay Init